MXCT Form 4: Director Disposes 10,684 Shares Under 10b5-1 Plan
Rhea-AI Filing Summary
Hemrajani Rekha, a director of MaxCyte, Inc. (MXCT), reported the sale of 10,684 shares of the issuer's common stock on 06/25/2025 at a weighted average price of $2.0945 per share. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2025. After the reported transactions, the reporting person beneficially owned 39,893 shares, with ownership reported as direct.
The Form 4 indicates the sales occurred in multiple transactions at prices ranging from $2.07 to $2.1212. The reporting person offered to provide detailed breakdowns of share counts by price upon request. No derivative transactions or other securities changes are reported in this filing.
Positive
- Sales executed under a documented Rule 10b5-1 trading plan, which supports transparency and reduces insider-timing concerns
- Reporting person retains a direct beneficial ownership of 39,893 shares after the transactions
- Price range and weighted average price disclosed and the filer offers to provide per-price breakdowns on request
Negative
- Director disposed of 10,684 shares, which could be viewed negatively by some investors even though it was pre-planned
Insights
TL;DR: Director sold a small stake under a pre-established 10b5-1 plan; remaining direct holding is 39,893 shares.
The sale of 10,684 shares at a weighted average of $2.0945 appears routine and was executed under a documented Rule 10b5-1 plan, which typically reduces insider-timing concerns. The transaction does not show additional derivative activity and leaves the director with a direct holding of 39,893 shares. From a market-impact perspective, the size of the sale relative to the disclosed remaining ownership suggests limited immediate signaling about company fundamentals.
TL;DR: Use of an adopted 10b5-1 plan indicates pre-planned sales, supporting governance transparency for insider transactions.
The filing explicitly notes the adoption date of the 10b5-1 plan and that sales were executed pursuant to it. This adherence to a structured trading plan is a positive governance practice because it provides an affirmative defense under Rule 10b5-1 and helps insulate the director from accusations of opportunistic trading. The Form 4 contains clear disclosure of transaction pricing range and offers further breakdowns upon request, which aligns with high disclosure standards for insider trades.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 10,684 | $2.0945 | $22K |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2025. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.07 to $2.1212, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
